Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-227 in healthy subjects.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A (RT) | Experimental | Period 1: Reference (Co-administration of AD-227A and AD-227B), Period 2: Test (AD-227) |
|
| Sequene B (TR) | Experimental | Period 1: Test (AD-227), Period 2: Reference (Co-administration of AD-227A and AD-227B) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Co-administration of AD-227A and AD-227B | Drug | Co-administration of AD-227A 1Tab. and AD-227B 1Tab., Per Oral |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum concentration of drug in plasma (Cmax) | Cmax of AD-227 | pre-dose (0hour) to 72hours |
| Area under the plasma concentration-time curve during dosing interval (AUCt) | AUCt of AD-227 | pre-dose (0hour) to 72hours |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Central Hospital | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000075222 | Essential Hypertension |
| ID | Term |
|---|---|
| D006973 | Hypertension |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Administration of AD-227 | Drug | Administration of AD-227 1Tab., Per Oral |
|